| ID | 1073 |
| Name of the vaccine | Adacel |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 10 to 64 years |
| Description of the vaccine | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis vaccine adsorbed (Tdap vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2005 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | Based on the immune response compared to US licensed Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) vaccine. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single 0.5 mL injection. First dose and Wound Management - 5 years. A repeat vaccination - 8 years |
| Mechanism of action | A serum tetanus antitoxin level of at least 0.01 IU/mL, is considered the minimum protective level. |
| Route of administration | Intramuscular |
| Indications | Active booster immunization against tetanus, diphtheria and pertussis. |
| Export | Distributed by - Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | Could be used for diphtheria and pertussis. |
| Side effects of vaccine | Injection site pain, swelling and erythema, myalgia, headache, malaise, body ache or muscle weakness and tiredness. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/119862/download |
| Other name | NA |
| Additional Links | https://www.rxlist.com/adacel-drug.htm#clinpharm
|